Navigation Links
Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Date:6/16/2013

Consultant Haematologist in the Department of Haematology at the Derriford Hospital in Plymouth, United Kingdom, presented the results of this study at the EHA Congress today. He explained, "To see these results from a single agent among MCL patients is quite significant and very promising. The fact that response rates continued to increase over time, with no new safety signals, is particularly reassuring."

In the second study among relapsed/refractory DLBCL patients, investigators examined whether ibrutinib would be more active in the Activated B-cell-like (ABC) subtype of DLBCL compared to the Germinal Center B-cell-like (GCB) subtype. The ABC subtype of DLBCL is dependent on the B-cell antigen receptor (BCR) pathway, of which BTK is a key element. Ibrutinib selectively inhibits BTK, with the aim of inhibiting malignant B-cell growth and proliferation. Results of this study show that:

  • Patients with the ABC subtype showed a preferential response to ibrutinib monotherapy compared to those with the GCB subtype (ORR = 41% vs 5%, respectively, p=0.007, Fisher's exact test).
  • Median overall survival (OS) was 9.7 months for the ABC subtype, compared to 3.35 months for the GCB subtype.
  • Safety data from 70 patients identified no new safety signals. Grade 3 or higher AEs were seen in greater than 3% of patients and included fatigue (9%), hyponatremia (9%), pneumonia (7%), dehydration (4%), and pleural effusion (4%).

"These results indicated that ibrutinib monotherapy was an effective treatment for some study patients who had ABC-subtype DLBCL," noted presenting investigator Sven de Vos, M.D., Ph.D., Associate Professor in the Department of Medicine at the UCLA Medical Center, Los Angeles, U.S.A., who presented the results at the EHA Congress today. "Given that patients wit
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
2. Updated HHS Mandate Continues Attack on Religious Freedom
3. Hoggan Scientific Unveils Updated ergoFET Force Gauge for Improved Force Evaluation
4. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
5. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
6. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. New PrEP Trial Results Among Injecting Drug Users Underscore That PrEP Works When Taken Consistently
9. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
10. Lakeland Industries to Report Fiscal First Quarter Financial Results and Conduct Conference Call
11. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Cardinal Health will today name ... winners of its prestigious Independent Pharmacy Best Practices Competition, ... of the nation,s largest gatherings of independent pharmacists. ... pharmacies from Ohio , ... – were selected for implementing exceptionally creative methods that ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
(Date:7/25/2014)... Laboratories, Inc. (NASDAQ: IDXX ) today reported ... 11% versus the prior year period to $390 million. ... of 2014 versus the prior year period was 9%, ... . Earnings per diluted share ("EPS") for the quarter ... year period to $1.10."In the second quarter, we continued ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28
... Study Reveals that Thoracic Endoluminal Grafting is a Feasible Alternative ... TO Open Surgical Repair, J Vasc Surg. 2007 Sep; 46(3):413-20. ... JA, Olsen DM, Shtutman A, Lucas LA, Wheatley G, Alpern J, Ramaiah V, Diethrich ... ...
... The National Institute of,Standards and Technology (NIST) ... in the Commerce Department,s Advanced Technology Program,(ATP), a ... awarded to the early-phase Michigan biotechnology company developing,drug ... and,other bone disorders. Velcura scientists have discovered ...
Cached Medicine Technology:Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 2Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 3Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 4Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 5Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 6NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease 2
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... 25, 2014 This is a ... of the Galactooligosaccharides (GOS) industry in Global ... of the industry, including definitions, applications and industry ... market analysis are provided with a focus on ... market. A comparison between the international and Chinese ...
(Date:7/25/2014)... Philadelphia, PA (PRWEB) July 25, 2014 ... that Valerie D. Weber, MD, MS, FACP, has been appointed ... , Weber will join Drexel from The Commonwealth Medical College, ... Sciences, associate dean for clinical affairs, and professor of medicine. ... of The Commonwealth Medical College, Weber had a major role ...
(Date:7/25/2014)... workers, especially men, may be at higher risk for type ... new study suggests. Also at special risk are shift ... moving around at various times of the day. The ... Alan Manevitz, a clinical psychiatrist at Lenox Hill Hospital in ... shifts disrupts many key body chemicals, creating a ripple effect ...
(Date:7/25/2014)... --, Treatment for lymphoma may lower men,s fertility, new ... which are cancers of the body,s white blood cells, ... reproductive years. For men, treatment for these cancers can ... their fertility within two years of treatment, the researchers ... of this significant side effect before treatment begins. ...
Breaking Medicine News(10 mins):Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2
... ALEXANDRIA, Va., Feb. 12 An article published in ... the American Medical Association helps physicians to better ... determine which end-of-life care options may be best for ... life have increased in recent years. With more ...
... Calif., Feb. 12 Fisher Vista, LLC, a marketing,and ... human resource,industries today announced that Kevin Grossman, who has ... president of its HRmarketer.com division. , ... overall responsibility of,HRmarketer.com and the HRmarketer Services Group. ...
... BASKING RIDGE, N.J., Feb. 12 Regado Biosciences, ... President and Chief Executive Officer, will be presenting ... Philadelphia, PA on Friday, February 20, 2009, at ... a review of the Company,s lead development product, ...
... of prescribing system to avoid ,alert fatigue, , , ... override electronic medication safety alerts and rely instead ... patients, which suggests that physicians find the alerts ... , Researchers looked at the electronic prescriptions ...
... 2009 Oral-B(R) Stages, the dental,professional,s #1 recommended ... a campaign in recognition of National Children,s Dental ... about the state of children,s,oral health in America, ... parents and,healthcare providers alike. In fact, tooth ...
... 12 Kovarus, Inc., a premier,technology consulting firm, and ... today jointly announced the launch of a new bike ... awareness of a good cause,the American Brain Tumor Association ... http://www.newscom.com/cgi-bin/prnh/20080708/AQTU138LOGO ) , The Studio ...
Cached Medicine News:Health News:JAMA Article Provides Guidance to Physicians on End-of-Life Care 2Health News:Kevin Grossman Named President of HRmarketer.com 2Health News:Docs Override Most Electronic Drug Warnings 2Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 2Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 3Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 4Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 5Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 6Health News:Biking for Fun, Sport, and Brain Tumor Awareness 2Health News:Biking for Fun, Sport, and Brain Tumor Awareness 3
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: